Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?
about
Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistanceA novel small molecule inhibitor of hepatitis C virus entryA new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutantsRational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus InfectionVirologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort.Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Rapid emergence of protease inhibitor resistance in hepatitis C virus.Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?Convergence and coevolution of hepatitis B virus drug resistance.Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients.Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitorHighlights from the 2012 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the search of an HIV cure.Low-level persistence of drug resistance mutations in hepatitis B virus-infected subjects with a past history of Lamivudine treatment.Ultrasensitive genotypic detection of antiviral resistance in hepatitis B virus clinical isolates.Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop.Treatment failure with new hepatitis C drugs.TMC435 for the treatment of chronic hepatitis C.Antimicrobial resistance and prudent drug use for Streptococcus suis.Update on HIV/HCV coinfection.Management and treatment of chronic hepatitis B in HIV-positive patients.Advances in treating drug-resistant hepatitis B virus in HIV-infected patients.Dual antiviral therapy for HIV and hepatitis C - drug interactions and side effects.Prevention and management of treatment failure to new oral hepatitis C drugs.Hepatitis C virus resistance to the new direct-acting antivirals.Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing.Drug interactions in HIV-infected patients treated for hepatitis C.Towards better antimicrobial susceptibility testing: impact of the Journal of Antimicrobial Chemotherapy.Development and Validation of Two Screening Assays for the Hepatitis C Virus NS3 Q80K Polymorphism Associated with Reduced Response to Combination Treatment Regimens Containing SimeprevirIn vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor.Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor.Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment.Hepatitis C therapy: highlights from the 2012 annual meeting of the European Association for the Study of the Liver.Identification of HCV protease inhibitor resistance mutations by selection pressure-based method.Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa-2b.Rapid antibiotic susceptibility testing by tracking single cell growth in a microfluidic agarose channel system.Evaluation of peptide nucleic acid array for the detection of hepatitis B virus mutations associated with antiviral resistance.
P2860
Q26740219-DA1C3443-6DAC-4D74-8A84-247A12A3FD6EQ28475468-91012266-0CB0-45FF-A9C8-D240FEFFA82CQ28541048-55B26461-ECDB-4526-8395-EA4CB5B6ACF3Q28545971-DDB39508-4BA9-4BAC-98D3-B229EF97AEAFQ34213161-1A10E57D-9420-4EEF-84FD-A5236F91B0C3Q34489239-568CFEB2-02E9-4325-B6C2-5536C4A6CE84Q34551913-0D346CB1-747E-488C-BB16-0E9EE6E3E8C7Q35491398-590E8706-83F2-469D-B902-F9EBEF0090A2Q35916670-C982802F-DF32-419C-8508-D1B007EA33DEQ35964704-7AF3A2F5-BF95-4C7E-822D-524D3FCDAA6CQ36104288-28124FA0-A9CF-43C7-8513-D1E297150909Q36320379-B810D83A-0A97-4674-BA84-C1EFB4A92E57Q36505336-0A81EF25-E9A0-43CC-96A8-7DDCDA56D7EBQ37247742-28B3F14B-EE1C-47E0-AEB2-C45EA781E89AQ37678183-410C43D6-DB1D-4861-B6E8-16293B6F7490Q37975543-E3524FB5-A438-4463-803A-2B8264B47A92Q38012160-1CD30927-A55D-49E3-9910-42BB90932879Q38107561-C4A16A77-4F2C-4ECD-948D-47239410F561Q38119893-75B7DAEB-CECF-46EA-BFCE-DFD9F964005CQ38203324-D48428ED-C70A-4CA7-8EA2-E304FE70FCEEQ38296047-88E06FD6-8FC7-4879-A86B-A698924F4B23Q38554604-837B2E23-AC8C-4CBD-AF2D-038E7EB84B3BQ38826624-4AEDCADB-BDB1-4C5B-8DD6-F46C0240C5EFQ38887954-7F73598D-1D62-4B71-8C78-203192B287DDQ39663398-7D55B7D1-0982-45D5-AD63-813818A0836FQ40143109-71A92903-3AD4-41D3-93EA-2B2735309638Q40361053-EF7A4071-D28F-4998-A0A7-17178A0F29CFQ41127462-0700E8F9-8F97-4ADF-9FFD-FC2234062595Q41585354-854131FE-D0A5-4E11-B7F2-721D3A2D943CQ42259160-481B57FA-EE50-48F3-AEF6-9A4E79D63AE9Q42286521-236EAC80-F55F-481B-A25E-FC498C935AC0Q42985405-F13C204E-2674-4C15-8272-58F5383EE378Q43023153-151A04FA-2210-4512-8D3E-D39E046E85E9Q43046741-DEDEE23C-DF59-42B0-9027-CDF0C1BEC5D5Q44034542-F9A616CD-9780-4121-8A97-AC91F70739DCQ45366377-FB9C3C0C-C15B-482E-BA5D-0FB2A1746E29
P2860
Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Why are there different dynami ...... and hepatitis B and C viruses?
@ast
Why are there different dynami ...... and hepatitis B and C viruses?
@en
Why are there different dynami ...... and hepatitis B and C viruses?
@nl
type
label
Why are there different dynami ...... and hepatitis B and C viruses?
@ast
Why are there different dynami ...... and hepatitis B and C viruses?
@en
Why are there different dynami ...... and hepatitis B and C viruses?
@nl
prefLabel
Why are there different dynami ...... and hepatitis B and C viruses?
@ast
Why are there different dynami ...... and hepatitis B and C viruses?
@en
Why are there different dynami ...... and hepatitis B and C viruses?
@nl
P2860
P3181
P356
P1476
Why are there different dynami ...... and hepatitis B and C viruses?
@en
P2093
Fabien Zoulim
P2860
P3181
P356
10.1093/JAC/DKN175
P407
P577
2008-07-01T00:00:00Z